BEIGF
What one share of Beone Medicines holds
Pharmaceutical Preparations
We are a leading global oncology company discovering and developing innovative treatments that are more accessible to cancer patients worldwide. In 2025, we generated total global revenue of approximately $5.3 billion, increasing revenue by approximately 40.2% from the prior year, while achieving net income of $286.9 million, net cash provided by operating activities of $1.1 billion and positive free cash flow of $941.7 million.
Beone Medicines’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $4.08 |
|---|---|
| Profit | $0.44 |
| Capex (buildings and equipment) | $0.10 |
| Free cash flow | $0.89 |
| Cash and investments | $3.47 |
| Debt | $0.78 |
| Book value | $3.52 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$0.30 | $0.06 | −$0.28 | — | $0.68 |
| 2017 | $0.44 | −$0.17 | $0.09 | −$0.06 | — | $1.13 |
| 2018 | $0.28 | −$0.93 | $0.10 | −$0.86 | — | $2.24 |
| 2019 | $0.55 | −$1.22 | $0.11 | −$1.08 | — | $1.20 |
| 2020 | $0.28 | −$1.50 | $0.11 | −$1.29 | — | $3.25 |
| 2021 | $0.98 | −$1.21 | $0.22 | −$1.29 | — | $4.59 |
| 2022 | $1.06 | −$1.49 | $0.24 | −$1.36 | — | $3.23 |
| 2023 | $1.81 | −$0.65 | $0.41 | −$1.27 | — | $2.60 |
| 2024 | $2.78 | −$0.47 | $0.36 | −$0.46 | — | $2.40 |
| 2025 | $3.62 | $0.19 | $0.13 | $0.64 | — | $3.03 |